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Abstract
cd T cells are a conserved population of lymphocytes that contrib-
utes to anti-tumor responses through its overt type 1 inflamma-
tory and cytotoxic properties. We have previously shown that
human cd T cells acquire this profile upon stimulation with IL-2 or
IL-15, in a differentiation process dependent on MAPK/ERK signal-
ing. Here, we identify microRNA-181a as a key modulator of
human cd T cell differentiation. We observe that miR-181a is
highly expressed in patients with prostate cancer and that this
pattern associates with lower expression of NKG2D, a critical medi-
ator of cancer surveillance. Interestingly, miR-181a expression neg-
atively correlates with an activated type 1 effector profile
obtained from in vitro differentiated cd T cells and miR-181a over-
expression restricts their levels of NKG2D and TNF-a. Upon in silico
analysis, we identify two miR-181a candidate targets, Map3k2 and
Notch2, which we validate via overexpression coupled with lucifer-
ase assays. These results reveal a novel role for miR-181a as critical
regulator of human cd T cell differentiation and highlight its
potential for manipulation of cd T cells in next-generation
immunotherapies.
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Introduction
Despite the recent advances in therapeutic strategies against cancer,
early tumor recurrence and novel metastasis formation indicate
resistance to current treatments. This urges the development of
alternative treatments for advanced stages of the disease. cd T cells
possess multiple anti-tumor characteristics, making them promising
candidates to be used in cellular and combination therapies (Gentles
et al, 2015; Silva-Santos et al, 2015, 2019). They provide IFN-c-
associated type 1 responses against cancer and express critical
determinants of tumor cell recognition, including their signature cd
TCR but also a variety of NK cell receptors (NKRs), among which
the natural killer group 2 member D (NKG2D) is of utmost impor-
tance (Lança et al, 2010; Correia et al, 2013; Silva-Santos et al,
2015; Wu et al, 2019). This notwithstanding, the cd T cell-based
clinical trials completed to date have shown objective responses of
only 10–33% (Gomes et al, 2010; Lo Presti et al, 2017). This modest
outcome could be explained by their deficient expansion and/or
dysregulated effector functions in vivo (Argentati et al, 2003; Bryant
et al, 2009; Gaafar et al, 2009; Kuroda et al, 2012).
Parallel investigations in both mice and humans have suggested
that the tumor microenvironment can subvert the anti-tumor type 1
effector cd T cell phenotype, either inactivating it (Marten et al,
2006; Gonnermann et al, 2015) or diverting into immunosuppres-
sive phenotypes (Peng et al, 2007; Hao et al, 2011; Ma et al, 2012;
Ye et al, 2013a, 2013b) or promoting the expansion of distinct pro-
tumor type 17 effector cd T cells (Rei et al, 2014; Wu et al, 2014;
Silva-Santos et al, 2019). Collectively, these limitations stress the
need to restore or enhance cd T cell type 1 inflammatory and cyto-
toxic properties in future immunotherapeutic approaches.
Based on this background, we have previously demonstrated that
the anti-tumor type 1 effector properties of cd T cells are selectively
acquired upon stimulation with IL-2 or IL-15, but not IL-4 or IL-7
(Ribot et al, 2014). The effects of IL-2/IL-15 depended on MAPK/
ERK signaling and induced de novo expression of the type 1 tran-
scription factors T-bet and eomesodermin. We followed those stud-
ies by exploring an additional layer of regulation of cd T cell
differentiation, namely, post-transcriptional mechanisms mediated
by microRNAs (miRNAs or miRs), which are still poorly character-
ized in cd T cells (Fiala et al, 2020), especially in the human setting
(Zhu et al, 2017).
MiRNAs are naturally occurring and evolutionarily conserved
endogenous small non-coding RNAs (18–25 nucleotides) that typi-
cally downregulate post-transcriptional gene expression by binding
to the 3ʹ untranslated region (UTR) of their target mRNAs and pro-
moting their degradation or inhibiting their translation (Ambros,
2004). Each precursor miRNA consists of two mature RNA
sequences—the 5p and 3p strands—whose designation is attributed
according to the directionality of the miRNA strand (Kozomara &
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Griffiths-Jones, 2014). Although it has long been proposed that the
5p strand is the one being loaded into the RNA-induced silencing
complex (RISC), recent evidence has disproven the idea that the 3p
strand is mainly degraded during miR biogenesis (Kozomara et al,
2019). In fact, both the 5p and 3p strands can be loaded onto the
Argonaute (AGO) family of proteins in an ATP-dependent manner
(Yoda et al, 2010) and can show differential expression levels
according to the pathophysiological context under study, namely, in
cancer (Mitra et al, 2015, 2020). Importantly, miRNAs exert their
regulatory functions in a highly combinatorial way: One miRNA can
regulate several mRNAs in parallel, and different miRNAs can target
one mRNA simultaneously, thus repressing its expression more effi-
ciently (Pons-Espinal et al, 2017). Since this post-transcriptional pro-
cess controls the expression of most mammalian genes, it is
particularly relevant to analyze its role in human cd T cell differenti-
ation. To date, only one study has highlighted a role for miR-125b-
5p and miR-99a-5p in human cd T cell activation and cytotoxicity
(Zhu et al, 2017), while the involvement of other miRs and their
potential impact on cd T cell responses to cancer remains unclear.
Here, we identify miR-181a as a novel molecular regulator of
human cd T cell functional differentiation. We demonstrate that
both its -5p and -2-3-p strands control cd T cell type 1 effector differ-
entiation and responsiveness by targeting Map3k2 and Notch2
mRNAs, and suggest a potential implication of this process in meta-
static cancer patients.
Results and Discussion
miR-181a is upregulated in peripheral cd T cells from metastatic
cancer patients
We investigated potential associations between miRNA expression
patterns and cd T cell dysfunction in metastatic cancer patients com-
pared to healthy controls. Reduced number and impaired pro-
inflammatory cytokine production have been previously reported in
circulating cd T cells from patients with melanoma (Argentati et al,
2003), glioblastoma (Bryant et al, 2009), breast (Gaafar et al, 2009),
and gastric (Kuroda et al, 2011) carcinomas. Here, we analyzed
patients of the cancer types with highest incidence in women
(breast) and men (prostate), both in the metastatic (stage IV) set-
ting. We found lower numbers of cd T cells in the peripheral blood
of both cohorts, and a decrease in their expression of NKG2D (sig-
nificant in the prostate cohort), when compared to the respective
(female or male) healthy controls (Fig 1A and B). We also observed
a tendency for reduced IFN-c production in the peripheral cd T cells
from the breast cancer patient cohorts, but this did not reach statisti-
cal significance (Fig 1C). Whereas the expression of miR-125b-5p
and miR-99a-5p, which have previously been reported to modulate
cd T cell activation and cytotoxicity (Zhu et al, 2017), was very low
and comparable to healthy controls (Fig 1D), we found—among
other candidates under study—miR-181a-5p and miR-181a-2-3p to
be upregulated in metastatic cancer patients, especially in the pros-
tate cancer cohort (Fig 1E), thus providing an interesting association
with cd T cell dysfunction (Fig 1A and B). Of note, the effects
observed were independent of patient age and treatment history.
miR-181a is known for its pleiotropic functions on ab T cell dif-
ferentiation, including controlling the Th1 response of human CD4+
T cells (Sang et al, 2015); however, the role of miR-181a has never
been addressed in human cd T cells.
miR-181a is downregulated upon type 1 effector cd
T cell differentiation
Given each individual’s history of infections, circulating cd T cells
in healthy donors are mostly functionally mature cells (Gibbons et
al, 2009; deBarros et al, 2011). By contrast, we have previously
shown that human cd thymocytes isolated from pediatric biopsies of
thymus are functionally immature and can be induced to acquire a
type 1/cytotoxic profile upon stimulation with IL-2 or IL-15, but not
IL-4 or IL-7 (Ribot et al, 2014). Based on our data described above,
we hypothesized that miR-181a might be downregulated during type
1 effector differentiation of human cd thymocytes. Consistent with
our hypothesis, we observed that the expression of both miR-181a
strands was significantly lower in in vitro differentiated (IL-2 cul-
tured) cd thymocytes compared to immature (IL-7 cultured) controls
(Fig 2A). In fact, all miR-181a species, including pre-miRNAs and
mature 5p and 3p strands, were downregulated upon IL-2 treatment
(Fig EV1A and B). Moreover, this downregulation of miR-181a (-5p
and 2-3p) expression was also found when comparing freshly iso-
lated (immature) cd thymocytes versus (mature) peripheral cd T
cells ex vivo (Fig 2B).
Given that human cd T cells comprise two major subsets, Vd1+
cells, that are more abundant in the thymus and non-lymphoid tis-
sues, and Vd2+ cells, which represent 60–95% of cd T cells in the
peripheral blood and in lymph nodes (Fichtner et al, 2020), we
assessed whether the composition of these populations could influ-
ence the levels of miR-181a expression in total cd T cell samples.
Although we found a higher level of miR-181a expression in the
Vd1+ cd T cell subset (Fig EV2A), the Vd1/Vd2 ratio did not corre-
late with miR-181a expression levels (Fig EV2B). We next antici-
pated that, besides IL-2, other cytokines might regulate miR-181a
expression and thus cultured cd thymocytes with a set of pro- and
anti-inflammatory mediators. IL-7 was used as control condition,
allowing cell survival without promoting their functional differentia-
tion (Ribot et al, 2014). Like IL-2, IL-15, which is also known to pro-
mote cd T cell functional differentiation (Ribot et al, 2014),
substantially downregulated the expression of both miR-181a
strands (Fig 2C). By contrast, TGF-b upregulated miR-181a expres-
sion, while other cytokines such as IL-4, IL-12, IFN-c, and TNF-a
showed no impact (Fig 2C). Collectively, these data revealed that
miR-181a expression is downregulated by drivers of type 1 effector
cd T cell differentiation, while being induced by immunosuppressive
cytokines, namely, TGF-b, which is typically enriched in the cancer
setting (Batlle & Massague, 2019). This may have pathophysiologi-
cal relevance, as TGF-b significantly enhanced miR-181a expression
in cd T cells isolated from the peripheral blood of healthy donors
(Fig 2D), thus mimicking the increased miR-181a levels displayed
by cd T cells from patients with prostate cancer (Fig 1E).
To further document the negative association of miR-181a with
type 1 effector cd T cells, we next analyzed the expression of molec-
ular hallmarks in various cd T cell samples at different stages of dif-
ferentiation. Namely, we used the same samples (i.e., freshly
isolated versus in vitro IL-7- or IL-2-cultured cd thymocytes) to mea-
sure the expression of miR-181a-5p and -2-3p, as well as the surface
protein levels of the type 1 cytotoxic mediator NKG2D, and the
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intracellular expression of the type 1 cytokines, IFN-c and TNF-a.
We observed a striking inverse correlation between the expression
of both miR-181a strands and the percentages of cd thymocytes pos-
itive for IFN-c, TNF-a, and NKG2D (Fig 2E), fully consistent with
our hypothesis that miR-181a negatively regulates type 1 effector cd
T cell differentiation. Interestingly, this inverse correlation was not
sustained in ex vivo peripheral blood cd T cells (Fig 2F), suggesting
a role for miR-181a during the early differentiation process, after
which cytokine production becomes constitutive in mature cells. On





Figure 1. Peripheral cd T cells from metastatic cancer patients display impaired effector functions and increased expression of miR-181a.
A cd T cell concentration in the peripheral blood from healthy donors and indicated metastatic cancer patients.
B RT–PCR analysis of the expression of NKG2D in cd T cells isolated from indicated samples.
C RT–PCR analysis of the expression of IFN-c and TNF-a in cd T cells isolated from the peripheral blood of healthy controls and metastatic cancer patients.
D RT–PCR analysis of the expression of miR-125b-5p and miR-99a-5p in cd T cells isolated from indicated samples.
E RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) in cd T cells isolated from indicated samples.
Data information: (A–E) Error bars represent the mean  SEM. CTRL F = Control Females (n = 25–27 independent biological samples); BC=Breast Cancer (n = 79–83
independent biological samples); CTRL M = Control Males (n = 19–20 independent biological samples); PC = Prostate Cancer (n = 29–36 independent biological
samples). Statistical analysis was performed using the unpaired Student’s t-test with Welch’s correction. ns, not significant. *P < 0.05, **P < 0.01, and ****P < 0.0001. All
experiments were performed with two technical replicates.
Source data are available online for this figure.
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peripheral cd T cells, which maintained the inverse correlation
between NKG2D and miR-181a levels (Fig 2F) as observed in cd thy-
mocytes (Fig 2E). Consistently, the upregulation of miR-181a
expression observed in TGF-b cultured peripheral cd T cells (Fig 2D)
associated with a lower percentage of NKG2D+ cells (Fig EV3).





Figure 2. miR-181a is downregulated upon type 1 effector cd T cell differentiation.
A RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) in cd T cells isolated from thymic biopsies, cultured for 11 days with IL-7 or IL-2 (n = 12–15
independent biological samples).
B RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) in cd T cells freshly isolated from thymic biopsies (Thymus) and PBLs (n = 6–14 independent
biological samples).
C, D RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) in cd T cells isolated from thymus (C) or from PBLs (D) and cultured with the indicated cytokines,
respectively for 11 days (C) or for 4–6 days (D). When indicated, cd PBLs were also co-cultured with an anti-TGF-b blocking antibody. Data are normalized to the
value obtained in IL-7 cultures (n = 4–10 independent biological samples).
E, F RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) versus FACS analysis of the expression of TNF-a (left panel), IFN-c (middle panel), and NKGD2 (right
panel) in cd T cells isolated from thymus (E) and PBLs (F). Samples were either freshly isolated or cultured for 11 days (cd thymocytes) or for 6 days (cd PBLs) with
the indicated cytokines (n = 5 independent biological samples).
Data information: (A–D) Error bars represent the mean  SEM. (A, C, D) Statistical analysis was performed using the paired Student’s t-test. (B) Statistical analysis was
performed using the Mann–Whitney U test. (E, F) The Pearson’s correlation coefficient (r) was used to measure the strength of association between two variables. ns, not
significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. All experiments were performed with two technical replicates.
Source data are available online for this figure.
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that regulate NKG2D and the pro-inflammatory cytokines in fully
mature peripheral cd T cells, our results collectively pointed toward
a role for miR-181a during effector cd T cell differentiation, which
we set out to test using a gain-of-function approach.
miR-181a overexpression impairs cd T cell differentiation
To formally test whether miR-181a is able to regulate effector cd T
cell differentiation, we used retroviral transduction to overexpress
miR-181a. We designed a construct in order to overexpress the
native stem-loop of miR-181a (containing both -5p and -2-3p
strands) in cd thymocyte cultures. Cells were freshly isolated, acti-
vated, transduced, and maintained in the presence of IL-7 and IL-2
to promote type 1 cytotoxic differentiation (Fig 3A). The expression
of the GFP reporter allowed us to identify the subpopulation that
integrated the retroviral construct (Fig 3B). As a technical control of
this set of experiments, we verified that sorted GFP+ cells transduced
with miR-181a vector displayed a significant increase in the expres-
sion of miR-181a (both the -5p and -2-3p strands) when compared
to cells transduced with the empty virus (Fig 3C). On the other
hand, as an internal control, we consistently analyzed the untrans-
duced GFP population, where miR-181a expression remained at
baseline (Fig 3C), and thus, no changes in any of the below-
mentioned readouts were expected.
miR-181a overexpression seemingly impaired cd T cell survival,
given the increase in Annexin V+ cells (Fig 3D) and the reduction in
expression of the anti-apoptotic genes Bcl2 and Bcl-xL (Fig 3E)
among the transduced (but not the untransduced) cd T cells. On the
other hand, miR-181a overexpression increased the percentage of
cells with a central memory profile (CD27+CD45RA), while reduc-
ing the percentage of cells displaying a typical na€ıve
(CD27+CD45RA+) and effector phenotype (CD27CD45RA+; Fig 3F).
Since previous studies reported that memory T cells arise from the
presence of high concentration levels of IL-2 (Berard & Tough, 2002;
Yurova et al, 2017), our results support a functional crosstalk
between miR-181a and IL-2-dependent signaling.
From a functional standpoint, we demonstrated that miR-181a
overexpression led to significant reductions in the percentages of
TNF-a+ and NKG2D+ cd T cells (Fig 3F). Interestingly, while the per-
centage of IFN-c+ cd T cells was not affected, we observed a
decrease in the percentage of TNF-a+ IFN-c+ subset, suggesting that,
in the type 1 effector differentiation pathway, miR-181a could also
regulate a step where IFN-c production would be induced from the
TNF-a+ population, as previously proposed for Vd2+ cd T cells and
NK cells (Skeen & Ziegler, 1995; Li et al, 2008). Of note, we
observed that miR-181a overexpression equally affected the percent-
age of TNF-a+ cells within Vd1+ and Vd2+ population (Fig EV4).
We further overexpressed miR-181a in mature cd T cells isolated
from healthy donor peripheral blood (Fig EV5A and B) and found a
significant albeit minor decrease in NKG2D levels, while type 1 dif-
ferentiation program remained intact (Fig EV5C). This is consistent
with our previous data pointing at an inverse correlation in periph-
eral cd T cells between the expression of miR-181a and NKG2D, but
not type 1 cytokine expression (Fig 2F). Of note, by comparing
GFPLow and GFPHigh subsets, either in cd thymocyte (Fig EV5D) or
PBL (Fig EV5E) cultures, we did not observe any dose effect of the
levels of miR-181a-bearing vector transduction. Overall, the differ-
ences between PBL and thymocyte cultures suggest that the
maturation status of cd T cells conditions their sensitivity to miR-
181a action, which is maximized at early stages of functional cd T
cell differentiation.
miR-181a targets Map3k2 and Notch2 mRNAs
To dissect the molecular mechanisms underlying miR-181a func-
tion, we went on to identify putative mRNA targets. For this, a
bioinformatical analysis using the mirDIP v4.1 database, coupled to
a Gene Set Enrichment Analysis (GSEA) of candidates involved in
Th1 differentiation and dysregulated in cancer, allowed us to pre-
dict a list of candidates based on the miR-181a-5 and -2-3p mature
sequences, common to both strands (Dataset EV1). Interestingly,
we could highlight the Notch and Mapk signaling pathways that
were already described to regulate the functional differentiation of
mature T lymphocytes (Ribot et al, 2014; Amsen et al, 2015; Duval
et al, 2015). Based on their putative binding sites, Map3k2 and
Notch2 were thus selected as potential miR-181a(-5p and -2-3p)
targets.
To experimentally validate these bioinformatics predictions, cd
thymocytes were transduced with either the empty or the miR-
181a viral vector and then differentiated in the presence of IL-2.
We next sorted the GFP+ transduced fraction and analyzed the
expression of Map3k2, Notch2, and Ptbp1 (as negative control) by
RT–PCR. As predicted, miR-181a overexpression in the type 1 dif-
ferentiation protocol induced a significant decrease in Map3k2 and
Notch2 mRNA levels (Fig 4A and B). We also analyzed the expres-
sion of genes involved in both MAPK (namely Atf2 and c-Fos) and
NOTCH (namely Hes1) signaling pathways and observed a reduc-
tion of the expression of all these signature genes within cd T cells
transduced with miR-181a, when compared to the empty control
vector (Fig 4B). We further noticed a reduction of additional genes
associated with both pathways, namely, p38 and Rbpj (Fig 4B).
Given the described role for both these genes as key regulators of
DNA methylation and histone acetylation processes (Clark et al,
2003; Schmeck et al, 2005; Giaimo et al, 2017; Rozenberg et al,
2018), such results point to an alternative upstream transcriptional
regulation or epigenetic alterations that can potentially be modu-
lated by miR-181a upregulation. To assess direct binding between
miR-181a and its target mRNAs, Map3k2, and Notch2, we
designed reporter constructs in a pmirGLO Dual-Luciferase to
include the Map3k2 or Notch2 30 UTR target regions for both miR-
181a-5p and -2-3p species (Fig 4A). However, due to the technical
limitations to include the entire region of interest from the 30 UTR
Notch2 candidate, we decided to amplify the binding site with the
higher percentile context score, as predicted by the TargetScan
v8.0 (Fig 4A). We included an additional negative control vector
containing a 30 UTR without miR-181a binding sites. We tran-
siently transfected these constructs into HEK293T cells together
with a vector plasmid for either miR-181a or an empty control.
Importantly, co-transfection of miR-181a could elicit a significant
repression of the luciferase activity of both Map3k2 and Notch2
mRNA targets, while not affecting the luciferase activity of the
control mRNA vector (Fig 4C). By contrast, no repression was
observed for the candidates or the control mRNAs in cells co-
transfected with the empty control. Of note, based on the target
score obtained from our in silico analysis (Dataset EV1), we also
assessed other promising candidate genes, namely, Irf4 and Stat1,
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Figure 3. miR-181a overexpression impairs cd T cell functional differentiation.
A Retroviral transduction workflow for cd thymocytes.
B Gating strategy for identification of the GFP+ versus GFP cells.
C RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) (normalized to the values obtained with the empty virus) in transduced (GFP+) and untransduced
(GFP) cd thymocytes, cultured with IL-7 plus IL-2 for 11 days (n = 4 independent biological samples).
D FACS analysis of the expression of Annexin V in miR-181a versus empty transduced (GFP+) and untransduced (GFP) cd thymocytes, cultured with IL-7 plus IL-2 for
11 days (n = 5 independent biological samples).
E RT–PCR analysis of the expression of Bcl2 and Bcl-xL (normalized to the values obtained with the empty virus) in transduced (GFP+) cd thymocytes, cultured with IL-7
plus IL-2 for 11 days (n = 5 independent biological samples).
F FACS-derived expression of indicated surface and intracellular markers in miR-181a versus empty transduced (GFP+) and untransduced (GFP) cd T thymocytes,
cultured with IL-7 plus IL-2 for 11 days (n = 7–11 independent biological samples).
Data information: (C–F) Error bars represent the mean  SEM. Statistical analysis was performed using the paired Student’s t-test. ns, not significant. *P < 0.05 and
**P < 0.01. All experiments were performed with two technical replicates.
Source data are available online for this figure.
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two transcription factors crucial for T cell differentiation (O’Shea
et al, 2011; Huber & Lohoff, 2014). While the expression of these
genes was downregulated in miR-181a transduced cd T cells
(Fig 4B), neither Irf4 nor Stat1 were validated as miR-181a targets
when first tested in luciferase assays (Fig 4C).
We performed additional luciferase assays by amplifying the 30
UTR regions of Map3k2 and Notch2 in both miR-181a-5p and -2-
3p potential binding sites, and included a control condition where
the amplified 30 UTR region was mutated in both binding sites.






Figure 4. miR-181a targets Map3k2 and Notch2 mRNAs.
A Putative binding sites of miR-181a(-5p and -2-3p) in the 30 UTR region of Map3k2 and Notch2. Potential miR-181a(-5p and -2-3p) gene targets were selected based
on predictions obtained in referenced mirDIP v4.1database. The predicted binding regions that were amplified for the luciferase assay are highlighted in gray.
B RT–PCR analysis of the expression of the indicated genes associated with Mapk, Notch, Irf4, or Stat1 signaling in sorted GFP+ cd thymocytes transduced with
empty or miR-181a viral vector. Data are normalized to the value obtained with the empty virus. Samples were cultured with IL-7 plus IL-2 for 11 days (n = 3–5
independent biological samples).
C Dual luciferase reporter assay performed to verify binding between miR-181a and Map3k2, Notch2, Irf4, or Stat1 mRNA. HEK293 T cells were co-transfected with a
pmirGLO Dual-Luciferase miRNA Target Expression Vector containing either the WT or mutated (Mut) 30 UTR target sites plus miR-181a. A negative construct
(without miR-181a binding sites) was included. Firefly/Renilla ratios were normalized to those obtained for the empty vector (n = 4 independent biological samples).
D RT–PCR analysis of the expression of miR-181a(-5p and -2-3p) versus MAP3K2 (left panel) or NOTCH2 (right panel) expression in cd T cells isolated from thymic
biopsies. Samples were cultured for 11 days with the indicated cytokines (n = 6 independent biological samples).
E–G RT–PCR analysis in circulating cd T cells of Map3k2 or Notch2 expression (E), Nkg2d or Tnfa expression (F), and NKG2D or TNF-a protein expression (G) after siRNA-
mediated knockdown of Map3k2 or Notch2. In each experiment, a control condition was also used where a nontargeting negative control siRNA was transfected.
cd were cultured with IL-7 for 4 days (n = 6 independent biological samples).
Data information: (B, C, E–G) Error bars represent the mean  SEM. Statistical analysis was performed using the paired Student’s t-test. (D) The Pearson’s correlation
coefficient (r) was used to measure the strength of association between two variables. ns, not significant. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. All
experiments were performed with two technical replicates.
Source data are available online for this figure.
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targets Map3k2 and Notch2 (Fig 4C). Here, it is important to high-
light the fact that having amplified a 30 UTR sequence containing
a potential binding site for both miR-181a-5p and -2-3p species
makes it impossible to clearly define which, or if both strands,
regulate Map3k2 and Notch2 mRNA expression. Analogously, the
simultaneous mutation of the predicted binding sites for both this
miR strands leading to a complete derepression, does not provide
a strict answer, and individual luciferase assays where only one
of the 30 UTR predicted (-5p or -2-3p) binding sites is mutated
would be required to address this question. This notwithstanding,
we correlated the levels of expression of both miR-181a-5p and -
2-3p with Map3k2 and Notch2 in cd thymocytes cultured with IL-
7 versus IL-2, and could clearly find an inverse correlation for
both miR-181a-5p and -2-3p species (Fig 4D). Of note, only the
correlations for the miR-181a-5p species reached a statistical sig-
nificance. These data, together with the observation of a predomi-
nance of the 5p strand in our samples, suggest that Map3k2 and
Notch2 are more likely repressed by miR-181a-5p in a physiologi-
cal context.
Finally, we performed siRNA targeting Notch2 and Map3k2 and
achieved a 20–30% reduction in the expression of these genes
(Fig 4E). This strategy phenocopied the effect of miR-181a overex-
pression on NKG2D expression in peripheral blood cd T cells, at
both the mRNA (Fig 4F) and protein (Fig 4G) levels. Altogether,
these data identified Notch2 and Map3k2, two known mediators of
T cell differentiation and cytotoxicity (Su et al, 2001; Amsen et al,
2007; Maekawa et al, 2008; Chang et al, 2011), as direct and rele-
vant targets of miR-181a in human cd T cells. Interestingly, Map3k2
has been shown to negatively regulate TGF-b-mediated T cell differ-
entiation, as Map3k2/ mice showed an abnormal accumulation of
Treg cells in the periphery, with a subsequent decrease in IFN-c pro-
duction (Chang et al, 2011). Additionally, genetic loss of Map3k2 in
vitro abrogated IL-2 production in T cells (Su et al, 2001). Likewise,
Notch2 is well known to modulate T cell activation and differentia-
tion. CD8+ T cells from Notch2-deficient mice display impaired cyto-
toxic properties caused by the inability to form a transcriptional
coactivator complex on the promoter of the gene encoding gran-
zyme B (Maekawa et al, 2008). Notch signaling also contributes to
the generation of human cd thymocytes (Van Coppernolle et al,
2012) and regulates peripheral cd T cell type 1 effector function and
cytotoxic activity (Gogoi et al, 2014). Of note, the miR-181 family
has been previously described to have a key role in modulating
Notch signaling, as deletion of miR-181a-1/b-1 inhibits the develop-
ment of Notch1 oncogene-driven T cell acute lymphoblastic leuke-
mia (Fragoso et al, 2012).
In sum, we propose that miR-181a acts as a brake during cd T
cell development, preventing their functional differentiation in the
human thymus. This could help explain why contrary to murine cd
T cells, which commit to effector functions in the thymus (Ribot et
al, 2009), human cd thymocytes remain functionally immature
(Ribot et al, 2014).
The miR-181 family encompasses six miRs, organized in three
clusters: miR-181a/b-1, miR-181a/b-2, and miR-181c/d (Zietara et
al, 2013). Importantly, the mature 5p strands for miR-181a-1 and a-
2 as well as b-1 and b-2 display identical sequences (Winter &
Krueger, 2019), indicating that these miRs might share some com-
mon regulatory functions. Within this family, miR-181a/b-1 is the
most extensively studied, probably due to its dynamic expression
throughout thymocyte development (Winter & Krueger, 2019). In
mice, miR-181a expression was shown to be higher in immature DP
thymocytes (Neilson et al, 2007; Kirigin et al, 2012), but lower in
more differentiated T cell populations, such as Th1 and Th2 effector
cells (Li et al, 2007). Mice deficient in miR-181a/b-1 displayed a
defect in thymic agonist selection (Zietara et al, 2013; Blume et al,
2016), impacting on invariant natural killer T (iNKT) cell and
mucosal-associated invariant T (MAIT) cell development (Zietara et
al, 2013; Winter et al, 2019), while retaining normal numbers of cd
T cells (Sandrock et al, 2015).
miR-181a is also known to regulate T cell functions in the context
of graft-versus-host disease, where mice receiving donor T cells with
enhanced miR-181a expression remained healthy, whereas T cells
lacking miR-181a/b-1 induced an exacerbated disease (Lee et al,
2016). Overexpression of different members from the miR-181a fam-
ily has been previously associated with an impairment of type 1
cytokine production in other immune partners. For instance, previ-
ous studies reported a decrease in IFN-c production upon overex-
pression of miR-181a-5p in murine CD8+ and human CD4+ T cells
(Sang et al, 2015; Amado et al, 2020).
Several studies have highlighted the need to investigate the 3p
strands, especially in a pathological context (Jazdzewski et al, 2009;
Mitra et al, 2015, 2020; Pink et al, 2015; Misono et al, 2018). In fact,
a recent pan-cancer analysis has revealed a miR cooperativity of
both (5p and 3p) strands to be able to regulate tumorigenesis and
patient survival (Mitra et al, 2020). Here, we used specific primers
to assess both miR-181a-5p and -2-3p expression in different cd T
cell samples and observed a consistent higher expression of the -5p
compared to the -2-3p strand. Of note, a recent elegant study in
mouse shows that miRNA activity is dependent on its concentration
and thus suggests that miRNA signatures should incorporate abun-
dance thresholds to establish their regulatory relevance (Rose et al,
2021).
Consistently, based on a mathematical model-derived predictions
to describe gene regulation on the single cell level, another pioneer
study had previously described that low expressed miRNA below
median have low or no inhibitory capability, while miRNAs over
the median and third quartile show a range of behavior that does
not reflect their expression levels (Lemus Diaz et al, 2017). Of note,
the authors propose that the gene regulatory function is actually a
dynamic and complex process, in which some miRNAs also display
their functionality according to the subcellular location, with low
functional and high expressed miRNA being at least partially located
in the nucleus, while some mid expressed but high functional
miRNAs are mainly seen in the cytoplasmic region (Lemus Diaz et
al, 2017).
Albeit the fact that miR-181a-5p was by far the most predominant
species present in our study, as the variation in expression of both
miR-181a-5p and -2-3p was consistent among the cd T cells, we pos-
tulated that both species could work together to regulate cd T cell
differentiation, and we thus overexpressed both upon transduction
of the complete miR-181a hairpin. We show that miR-181a overex-
pression impairs human cd T cell differentiation into TNF-a + effec-
tors, while also reducing the expression of NKG2D. By contrast, we
show that miR-181a seemingly did not affect differentiation into
IFN-c producers. This highlights the complexity of action of
miRNAs, including the members from the miR-181a family, in fine
tuning a restricted gene expression profile by acting on specific
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targets. Of note, since we found very small subsets of IL-4+ (1–2%)
or IL-17A+ (< 1%) cd T cells, we have not addressed the potential
role of miR-181a in type 2 or type 17 differentiation of human cd
T cells.
The concept of miR-181a as a brake to functional cd T cell differ-
entiation is supported by the fact that its two main cytokine drivers,
IL-2 and IL-15, downregulate miR-181a(-5p and -2-3p) expression.
Conversely, we found the immunosuppressive cytokine, TGF-b, to
be the main inducer of miR-181a(-5p and -2-3p) expression in
human cd T cells. We thus propose that the upregulation of miR-
181a expression by TGF-b may be part of a negative feedback loop
that would prevent excessive inflammation in order to limit tissue
damage (Li et al, 2017). On the other hand, established cancer set-
tings are often rich in TGF-b (Batlle & Massague, 2019), and there-
fore, we speculate that miR-181a upregulation may trigger cd T cell
functional exhaustion in prostate cancer, as previously reported for
other miRs in human T cells in the context of breast cancer (Zhao et
al, 2016) or non-small-cell lung cancer (Wan et al, 2018). Interest-
ingly, previous studies demonstrated that tumor-derived exosomal
miRs can alter T cell activation or effector profile, thus highlighting
potential tumor evasion mechanisms (Ye et al, 2014; Bland et al,
2018).
While miR-181a can impact both NKG2D expression and type 1
cytokine production in differentiating cd thymocytes, it can no lon-
ger regulate the latter process in cd T cells isolated from the periph-
eral blood, which are mostly mature (Gibbons et al, 2009; DeBarros
et al, 2011; Ribot et al, 2014), with particular effector/memory phe-
notypes (Dieli et al, 2003). This suggests that miR-181a controls
type 1 cytokine production at early stages and within a limited time
window of cd T cell differentiation and further implies that cd T cell
maturation status, which presumably associates with dynamic rep-
ertoires of mRNA targets, dictates sensitivity to miR-181a. The
inverse correlation between miR-181a(-5p and -2-3p) expression
and NKG2D levels was found in both differentiating cd thymocytes
and in circulating cd T cells; and reduced NKG2D expression associ-
ated with high miR-181a(-5p and -2-3p) levels in cd T cells isolated
from the blood of patients with prostate cancer. NKG2D plays a criti-
cal role in tumor surveillance, by promoting target recognition and
cytotoxicity, and thus is particularly relevant to prevent tumor cell
metastasis (Sivori et al, 2019). Furthermore, the NKG2D/NKG2DL
pathway is being targeted for cancer treatment, and an improved
understanding of its post-transcriptional regulation may open new
avenues for next-generation immunotherapies.
Concluding remarks
Our study constitutes an important addition to the molecular mecha-
nisms that govern the acquisition of type 1 effector functions of
human cd T cells, and especially at the post-transcriptional level
which is less explored. We propose a two-step model for a dynamic
miR-181a-based regulation of cd T cell differentiation, which is
finely tuned within pro- versus anti-inflammatory environments.
First, in the thymus, elevated concentrations of TGF-b (Jurberg et
al, 2015) would induce high levels of miR-181a, thus impairing
Map3k2 and Notch2 expression, which ultimately would help
restrain cd T cell differentiation. Then, at peripheral inflamed sites,
IL-2 or IL-15 signals would reduce cd T cell expression of miR-181a,
thus releasing the functional brake to promote type 1 cytokine and
NKG2D expression. This could potentially be mediated by an
increase in miR-181a mRNA targets expression, such as Map3k2 or
Notch2, combined with other key regulatory mechanisms, such as
epigenetic modifications. However, high miR-181a expression levels
can be induced de novo in peripheral cd T cells by TGF-b, which
leads to reduced expression of NKG2D as a possible mean to prevent
collateral tissue damage. We postulate that tumors take advantage
of this mechanism to settle their immune evasion. Thus, we believe
our work has pathophysiological implications in cancer immunity
and inflammatory disease settings. Importantly, miR-based thera-
pies already exist or are currently under clinical trials, as it is the
case for the thyroid cancer combined therapy ThyraMIR/
ThyGeNEXT, or the Miravirsen treatment against hepatitis C
(Lanford et al, 2009; Bonneau et al, 2019). This clearly highlights
the potential of using miR-based strategies in the design of new (or
improved) cd T cell-based clinical protocols, toward their effective
application in cancer treatment.
Materials and Methods
Patients and healthy donor samples
12 ml of peripheral blood was collected at baseline (before starting
new line of therapy) from 119 patients diagnosed with stage IV
breast or prostate cancer (breast cancer patients n = 83, 52.3 
11.9 years old; prostate cancer patients n = 36, 70.9  8.5 years
old) and from 47 healthy donors (female healthy donors n = 27,
46.3  11.3 years old; male healthy donors n = 20, 49.0 
8.9 years old), followed at CHULN-Hospital Santa Maria, Lisbon.
Thymic specimens were routinely obtained during pediatric correc-
tive cardiac surgery (from new-born to 10-year-old children),
performed at Hospital de Santa Cruz Carnaxide. For RT–PCR analy-
sis of miR expression, 15 thymic samples were collected from
female (n = 7) and male (n = 8) donors. For miR retroviral trans-
duction, 11 thymic samples were collected from female (n = 7) and
male (n = 6) donors. Concentrated leukocyte suspension samples
(buffy-coats) from healthy donors were collected at Instituto
Português do Sangue e Transplantaç~ao. For RT–PCR analysis of miR
expression, 13 buffy-coat samples were collected from female
(n = 5) and male (n = 8) donors. For miR retroviral transduction, 5
buffy-coat samples were collected from female (n = 3) and male
(n = 2) donors. For siRNA transfection experiments, 6 buffy-coat
samples were collected from female (n = 4) and male (n = 2)
donors. All samples were collected with informed consent and
approved by the Ethical Board of the Academic Medical Center of
Lisbon CAML (CHLN/FMUL/IMM). Experiments are conformed to
the principles set out in the WMA Declaration of Helsinki and the
Department of Health and Human Services Belmont Report.
Lymphocyte preparations
Blood samples were separated on a Histopaque-1077 density gradi-
ent. Thymic samples were cut into small pieces (< 0.5 cm2) and
smashed into a 70-lm filter and Histopaque-1077 (Sigma-Aldrich)
density gradient. cd T cells were isolated by magnetic cell sorting
(MACS) by positive selection, according to manufacturer’s instruc-
tions (Miltenyi Biotec).
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Cell culture
MACS isolated cd T cells were cultured at a density of 106 cells/ml
in round-bottom 96-well plates with RPMI 1640 and 2 mM L-
glutamine supplemented with 10% FBS, 1% of sodium pyruvate,
1% of HEPES, 1% of minimum essential amino acids (NEAA), and
1% of penicillin and streptomycin (Pen/Strep; all from Invitrogen
Life Technologies).
For the analysis of miR-181a expression, cd T cells were cultured
with the following cytokines: IL-2, IL-7, IL-12, IL-15, TNF-a, IFN-c,
IL-4, IL-10, and TGF-b (all from PeproTech, 10 ng/ml). Anti-TGF-b
blocking antibody (1D11.16.8, BioXCell, 10 lg/ml) was added when
mentioned. cd T cells from buffy-coats or thymic biopsies were cul-
tured for 4–6 or 11 days, respectively, and then pelleted, frozen,
and stored for posterior analysis.
For retroviral transduction experiments, cd T cells were cultured
at a 5 × 105 cell/ml density, round-bottom 96-well plates with RPMI
1640 and 2 mM L-glutamine supplemented with 10% FBS, 1% of
sodium pyruvate, 1% of HEPES, 1% of minimum essential amino
acids (NEAA), and 1% of penicillin and streptomycin (Pen/Strep; all
from Invitrogen Life Technologies). On the transduction days, cells
were transferred into flat-bottom 96-well plates in a DMEM medium
(Invitrogen Life Technologies) supplemented with 15% FBS, 1% of
HEPES, 1% NEAA, and 1% of Pen/Strep. Indicated cytokines were
added when mentioned (all from PeproTech, 10 ng/ml).
For retrovirus generation, the human embryonic kidney 293 cells
with large T antigen (HEK293T) cell line (ATCC CRL-11268TM) and
the NIH/3T3 cells (ATCC CRL-1658TM) were grown in T 175 flasks
in DMEM supplemented with 15% FBS, 1% of HEPES, 1% of NEAA,
and 1% of Pen/Strep, during 4–5 days. After reaching the required
cell number for the experiment, the HEK293T cell line was cultured
in 10 cm tissue culture plates (Sigma-Aldrich TPP) at a density of
5 × 105 cells/ml, while the NIH/3T3 cells were cultured in flat-
bottom six-well plates (Corning Incorporated) at a density of 7 ×
104 cells/ml.
For dual luciferase assays, HEK293T cell line was cultured in
flat-bottom 12-well plates at a density of 1.5 × 105 cells/ml, in
DMEM supplemented with 15% FBS, 1% of HEPES, 1% of NEAA,
and 1% of Pen/Strep.
For siRNA targeting, cd T cells were cultured at a 5 × 105 cell/ml
density in round-bottom 96-well plates with RPMI 1640 and 2 mM
L-glutamine supplemented with 10% FBS, 1% of sodium pyruvate,
1% of HEPES, and 1% of minimum essential amino acids (NEAA),
without antibiotics. Indicated cytokines were added when men-
tioned (all from PeproTech, 10 ng/ml).
All incubations were performed at 37°C in a 5% CO2
environment.
Retroviral transduction of miR-181a
The native precursor stem-loop of the hsa-miR-181a was cloned
into the MSCV-IRES-GFP vector (Addgene #9044), modified to
include a PGK-GFP-WPRE sequence (pMIG-PGW) as previously
described (Schmolka et al, 2018), using human genomic DNA as a
template and the following primers for hsa-miR-181a: forward
primer, CGCCGGAATTAGATCTCCTAGTATATAGCAGATCCCCAAT
and reverse primer, AACCTCGAGAGATCGACTGCTCCTTACCTTGTT
GAA. Purified PCR product was then transformed in the StellarTM
Competent Cells according to the manufacturer’s protocol PT5055-2
(Clontech, 2011). The plasmid pMIG-PGW either empty (pMIG-
PGW-Empty) or containing the miR-181a stem-loop fragment was
extracted from the bacteria using the GeneJET Plasmid Miniprep Kit
(Thermo Fisher Scientific). The presence of the miR insert was con-
firmed by DNA digestion using proper restriction enzymes and ana-
lyzing the fragment lengths in an agarose gel. Validation of the
results was performed by analyzing the sequences, expected and
obtained, with the SnapGene Viewer Software V. 3.1.4. The viral
supernatant was produced by transfecting the plasmids pMIG-PGW
(either empty or with miR-181a), pCMV-VSV-G and pCL-Eco with
the Opti-MEM (Life Technologies) and the X-tremeGENE9 DNA
Transfection Reagent (Roche) into the HEK293T TAT cells cultured
in 10 cm culture plates (x-TremeGene, 2013). Titers of infectious
virus were determined by transducing 100,000 NIH/3T3 cells per
well in a NuncTM six-well plate, with 8 lg/ml of polybrene during a
60 min centrifugation at 32°C, 974 g. Cells were infected at a multi-
plicity of infection of 2.5 or 5, which resulted in a transduction effi-
ciency between 65–80 and 85–98%, respectively.
The pMIG-PGW vector encodes a green fluorescent protein (GFP)
that allows to assess the transduction efficiency.
For retroviral transduction of cd T cells, the latter were cultured
in 96-well plate and stimulated overnight with plate-bound mAbs
anti-CD3 (1 lg/ml; HIT3a; eBioscience) and anti-CD28 (1 lg/ml;
CD28.2; eBioscience) in a media supplemented with IL-2 and IL-7
(10 ng/m PeproTech), for 11 days. 5 × 105 cd T cells per well were
transduced with pMIG-PGW-miR-181a or a pMIG-PGW-Empty vec-
tor. The transduction was performed with 4 lg/ml of polybrene
(Sigma) followed by a 45 min centrifugation at 32°C, 974 g. One
week after the last transduction, cd T cells were stained with mAbs
for FACS analysis. Alternatively, cd T cells were electronically
sorted, based on their GFP expression, in order to assess miR-181a
transduction efficiency by RT–PCR.
siRNA gene silencing of Map3k2 and Notch2
cd T cells were cultured in 96-well plate as previously described and
stimulated overnight with plate-bound mAbs anti-CD3 (1 lg/ml;
HIT3a; eBioscience) and anti-CD28 (1 lg/ml; CD28.2; eBioscience)
in a media supplemented with IL-7 (10 ng/ml PeproTech). siRNAs
were pre-incubated with the DharmaFECTTM transfection reagent for
20 min, according to the manufacturer’s protocol (Dharmacon).
Cells were then transfected with either an siRNA against Map3k2,
Notch2, or a negative control siRNA (nontargeting) and analyzed
after 48 h. siRNAs were obtained from Dharmacon (ON-
TARGETplus Human) and used at a concentration of 500 nM.
Flow cytometry (FACS) analysis
For intracellular cytokine staining, cells were stimulated with PMA
(50 ng/ml, Sigma-Aldrich; P-8139) and Ionomycin (1 lg/ml, Sigma-
Aldrich; I-0634) for 3 h at 37°C, with the addition of Brefeldin A
(BFA; 10 lg/ml, Sigma-Aldrich; B-7651). Cells were stained for the
identified cell surface markers for a period of 30 min at 4°C, fixed
with Fixation/Permeabilization buffer (eBioscience) supplemented
with BFA and left to incubate for 30 min at 4°C. Alternatively, to
ensure the maintenance of GFP expression, retrovirally transduced
cd T cells were fixed with 4% Paraformaldehyde (Sigma-Aldrich).
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Cells were then permeabilized with Permeabilization buffer
(eBioscience) and resuspended in Fc block (eBioscience) for 10 min
at 4°C. For intracellular cell, staining cells were incubated for
30 min at 4°C in 50 ll of Permeabilization buffer containing the
indicated antibodies.
The following anti-human fluorescently labeled mAbs were used
(Table 1): anti-Vd1-PE (REA173; Miltenyi Biotec), anti-Annexin V-
APC (VAA-33), anti-IFN-c-APC (4S.B3) (all from eBioscience), anti-
TNF-a-PE-Cy7 (MAb11), anti-NKG2D-BV421 (1D11), anti-Vd2-PerCP
(B6), anti-IL-2-BV510 (MQ1-17H12), anti-CD45RA-BV510 (HI100),
and anti-CD27-BV605 (O323; all from Biolegend). Live cells were
identified through a staining with the LIVE/DEADTM Fixable Near-IR
Dead Cell Stain Kit (Life technologies), for a period of 30 min at
4°C, and dead cells were electronically excluded. Transduced cells
were identified by the GFP+ fluorescence. Cells were sorted on FACS
Aria (BD Biosciences) and samples were acquired using FACS
Fortessa (BD Biosciences) cell analyzer. All data were analyzed
using FlowJo X 10.0.7r2 software (Tree Star).
RNA isolation, cDNA production, and real-time PCR
For miR and mRNA expression analysis, total RNA was extracted
from MACS isolated cd T cells or electronically sorted cd T cells by
using the miRNeasy Mini Kit (Qiagen) according to the manufac-
turer’s protocol. RNA concentration and purity were determined
using the NanoDropTM 2000 spectrophotometer (Thermo Fisher
Scientific).
For miR, reverse transcription was performed with miRCURY
LNATM Universal RT Kit (Qiagen). For mRNA, reverse transcription
from total RNA was performed with random oligonucleotides (Invi-
trogen) using Moloney murine leukemia virus reverse transcriptase
(Promega). Total RNA was reverse-transcribed into cDNA using the
T100 Thermal Cycler (Bio-Rad), and all quantitative PCRs (qPCRs)
were performed in MicroAmp Optical 384-Well Reaction Plate
(Applied Biosystems) using the RT–PCR ViiA7TM system (Applied
Biosystems).
For miR expression analysis, LNATM PCR primer sets (Qiagen)
were used on the cDNA previously obtained and relative quantifica-
tion of specific miRs to small nucleolar RNA C/D Box 44 (SNORD44)
reference was carried out using SYBR on ABI ViiA7TM cycler
(Applied Biosystems). For mRNA expression analysis, primer sets
(Sigma) designed by Universal Probe Library Assay Design Center
(Roche) were used on the cDNA previously obtained and relative
quantification of specific cDNA species to endogenous references
GUSB or PSMB6 was carried out using SYBR on ViiA7 cycler
(Applied Biosystems).
For standard curve construction and sample absolute quantifica-
tion, three unmodified oligoribonucleotides corresponding to hsa-
miR-181a-5p (AACAUUCAACGCUGUCGGUGAGU), hsa-miR-181a-1-
3p (ACCAUCGACCGUUGAUUGUACC), and hsa-miR-181a-2-3p
(ACCACUGACCGUUGACUGUACC) were synthesized (Eurofins
Genomics). Different dilutions of oligoribonucleotides in RNase-free
water were prepared, and the appropriate dilution was reverse-
transcribed to cDNA in 10 ll total reaction, using the miRCURY
LNATM Universal RT Kit (Qiagen). A tenfold dilution series over six
points were prepared from the cDNA and used as templates for
qPCR. The standard curve was constructed by plotting Cq values
against the logarithmic copy numbers of the calibrator oligoribonu-
cleotides. The amount of an unknown sample was quantified by
interpolating the Cq values in the standard curve.
For pre-miR-181a-1-3p and pre-miR-181a-2-3p expression analy-
sis, specific primers were ordered (Eurofins Genomics) to allow for
the amplification of each respective stem-loop region, as follows:
pre-miR-181a-1-3p forward primer, GAACATTCAACGCTGTCGGT,
and reverse primer, GTTAGCCATAGGGTACAATCAACG; pre-miR-
181a-2-3p forward primer, TATCAGGCCAGCCTTCAGAGG, and
reverse primer, GTACAGTCAACGGTCAGTGGTT. Relative quantifi-
cation of specific cDNA species was performed as explained above.
Data were analyzed using ViiA7TM software v1.2.1.
Dual luciferase reporter assay
The 30 UTR of Map3k2, Notch2, Irf4, Stat1, and a negative control
(Ptbp1) were cloned into pmirGLO vector (Promega) using human
genomic DNA as a template and the following primers: Map3k2 for-
ward primer, GCTCGCTAGCCTCGAGTTGCCATACTCTTGGTTGCT,
and reverse primer, CGACTCTAGACTCGAGTGTTGCACGTACCAC
ACTGTA; Notch2 forward primer, GCTCGCTAGCCTCGAGTTCCCG
GTATCCCTTGGAGT, and reverse primer, CGACTCTAGACTCGA
GTTCACTTAAGGAATGTTACAAACCA; Irf4 forward primer, GCTC
GCTAGCCTCGAGCGTCCAATTGACTGCCCTCT, and reverse primer,
CGACTCTAGACTCGAGGGAGATCCACCTGCATCGAG; Stat1 for-
ward primer, GCTCGCTAGCCTCGAGGACAGCAGAGCGCCTGTATT,
and reverse primer, CGACTCTAGACTCGAGAACCATGCCGAATTC
CCAAAG; Ptbp1 forward primer, GCTCGCTAGCCTCGAGGACC
CAGGTCCAAGTTCTCG, and reverse primer, CGACTCTAGACTCGA
GAAAAGCCCACGTACCTCTGG. Primers are available upon request
(Sigma). In a second round of assays, mutations in the predicted tar-
get sequences for both miR-181a-5p and -2-3p of the 30 UTR of
Map3k2 and Notch2, were introduced by gene synthesis (GeneCust
Europe). Each luciferase reporter vector carrying one of the 30 UTR
sequences described above was co-transfected with either the pMIG-
PGW-miR-181a or the control pMIG-PGW-Empty vector into the
HEK293T cell line using Lipofectamine 2000 (Thermo Fisher Scien-
tific). After 48h, firefly and Renilla luciferase activity were measured
by using the Dual-Glo Luciferase Assay System (Promega). Renilla
luciferase activity served as the internal control and results were
expressed as relative luciferase activity, normalized to the empty
vector.
Table 1. List of antibodies used for FACS analysis.
Specificity Clone Fluorochrome Cat # Origin




Annexin V VAA-33 APC 88-8007-
74
eBioscience
IFN-c 4S.B3 APC 502512 eBioscience
TNF-a MAb11 PE-Cy7 502930 Biolegend
NKG2D 1D11 BV421 320822 Biolegend




CD45RA HI100 BV510 304142 Biolegend
CD27 O323 BV605 302830 Biolegend
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Statistical analysis
Statistical analysis and data presentation were performed using
GraphPad Prism 8 software (La Jolla). The values presented are
mean  SEM of an independent experiments. The statistical signifi-
cance of differences between two populations was assessed using
either the two-tailed nonparametric Mann–Whitney U test or the
Student’s t-test as indicated in the figure legends. The Pearson’s cor-
relation coefficient (r) was used to measure the strength of associa-
tion between two variables. Correlation Strength (r): 0.1–0.3 weak;
0.3–0.5 moderate; 0.5–1.0 strong. Outlier analysis was applied using
the Grubbs’ test (Alpha = 0.01) and the ROUT test (Q = 1%). Statis-
tical significance was indicated at *P < 0.05, **P < 0.01,
***P < 0.001, and ****P < 0.0001.
Data availability
This study includes no data deposited in external repositories.
Expanded View for this article is available online.
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